Citurgia Biochemicals Board of Directors

Get the latest insights into the leadership at Citurgia Biochemicals. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Kashi Nath Jha Executive Director
Mr. Vivek Singh Ind. Non-Executive Director
Ms. Reena Devi Mandal Ind. Non-Executive Director
Mr. Jitendra Ind. Non-Executive Director
Mr. Dharmendra Non Exe.Non Ind.Director
Mr. Subhash Sahu Non Exe.Non Ind.Director

Citurgia Biochemicals Share price

CITURGIA

60.48

2.88 (5.00%)
Last updated on 17 Feb, 2026 | 15:44 IST
alert_iconwatchlist_icon
BUYSELL
Today's High

60.48

Today's Low

60.48

52 Week Low

47.40

52 Week High

60.48

alert_iconThe current prices are delayed, login to your account for live prices

Citurgia Biochemicals FAQs

The board at Citurgia Biochemicals consists of experienced professionals, including Mr. Kashi Nath Jha , Mr. Vivek Singh , and others, overseeing the company’s strategic and corporate governance.

Directors at Citurgia Biochemicals are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Kashi Nath Jha is the current chairman at Citurgia Biochemicals.

Executive directors at Citurgia Biochemicals are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Citurgia Biochemicals adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Citurgia Biochemicals, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.